Cardio3 pitches its stem cell, CAR-T pipeline to U.S. investors

Cardio3 Biosciences (EBR:CARD) is set to become the latest European biotech to pitch up on Wall Street in search of cash from public investors. And with a clinical-phase CAR-T asset in its pipeline, the Belgian biotech stands a chance of tapping into …

[Read the full article here]

Comments are closed.